Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

n the Committed Equity Financing Facility with Kingsbridge, and our plans regarding collaborations and other partnering activities. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by the company with the SEC.

(Tables Follow)

    Micromet, Inc.
    Condensed Consolidated Balance Sheets
    (In thousands, except par value)

                                               December 31,   December 31,
  
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , ... patient safety, today announced the appointment of Mary ... With 28 years of experience preparing companies for ... 2013 as Executive Vice President of Corporate Development and ... performance improvement business , as well as corporate strategy ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... Scheduled for October 31, 2008 at 11:00 am EASTERN, ... TRIB ), a leading developer and manufacturer of ... report,financial results for the third quarter of fiscal year ... a conference call for that same,day, Friday, October 31, ...
... Company Overview-, PRINCETON, N.J. and SAN DIEGO, ... on the development of medicines with,novel mechanisms of ... a corporate overview at the 2008 BIO Investor ... summarize the,current status of the company including the ...
... Oct. 23 United,Therapeutics Corporation (Nasdaq: UTHR ... third quarter financial results before market open on,Thursday, ... a half-hour teleconference on Thursday,October 30, 2008, at ... dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A rebroadcast ...
Cached Biology Technology:Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008 2Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum 2
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/28/2014)... Entomological Society of America (ESA) is pleased to announce ... Member of the Society. Honorary Membership acknowledges those who ... significant involvement in the affairs of the Society that ... are selected by the ESA Governing Board and then ... be honored at the Awards Ceremony at Entomology 2014, ...
(Date:8/28/2014)... Research Careers) Program has announced the travel award recipients ... 18 22, 2014 in San Diego, California. ... students, post doctorates and scientists from underrepresented groups into ... encourage the participation of young scientists at the American ... 16 awards totaling $29,600., The FASEB MARC Program is ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... rats in combination with an animal model of obstructive nephropathy, ... in the development of kidney disease. This research is ... kidney disease is difficult to study since it takes a ... Ph.D. of the Instituit Louis Bugnard inFrance. "This animal ...
... by computer scientists at Washington University in St. Louis ... gene transcription start sites and where the first splice ... , The modification to the gene prediction software TWINSCAN ... science at Washington University in St. Louis, together with ...
... mighty feat for a microscopic fungus built from threadlike ... several billion tons of nutrients out of the soil ... University-supported research on the movement of nitrogen brings into ... nearly all of Earth's food chains. , "Ignorance (about ...
Cached Biology News:Modification of program enables prediction of gene transcription 2Modification of program enables prediction of gene transcription 3Digging in the dirt for life's biochemical foundations 2
Recombinant Rat Fas Ligand/TNFSF6...
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Biology Products: